آمریکا در پی تولید بیشتر داروهای ژنریک؛ هند موانع را نشان می‌دهد

The Trump administration has made it a priority to bring the manufacturing of generic drugs back to the United States, arguing that it will lower costs and ensure a reliable supply of essential medicines. But a recent trip to India, a global hub for generic drug production, revealed just how difficult that will be.

India has become the world’s pharmacy, producing a large share of the generic drugs used in the United States. Its success is built on a combination of factors, including low labor costs, a skilled workforce and a well-developed pharmaceutical industry.

American companies that have tried to move production back to the United States have found that they cannot compete with the low costs in India. They also face challenges in building new manufacturing facilities and finding qualified workers.

“We want to make more drugs here, but it’s not going to be easy,” said one pharmaceutical executive who recently visited India. “The cost of labor is much higher in the United States, and it takes a long time to build a new factory.”

The Indian pharmaceutical industry is also benefiting from a supportive government policy. The government has invested heavily in the industry and has created a regulatory environment that is favorable to drug manufacturers.

“The Indian government is committed to supporting the pharmaceutical industry,” said a government official. “We believe that the industry is a key driver of economic growth and job creation.”

The challenges facing the Trump administration are not insurmountable, but they are significant. If the administration is serious about bringing generic drug manufacturing back to the United States, it will need to address the issues of cost, labor and regulation.